Immucell Corp(ICCC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 118.18 | EPS (ttm) | 0.08 | Insider Own | 37.77% | Shs Outstand | 9.1M | Perf Week | -0.85% |
| Market Cap | 0.09B | Forward P/E | - | EPS next Y | - | Insider Trans | 0.23% | Shs Float | 5.7M | Perf Month | -9.45% |
| Enterprise Value | 0.09B | PEG | - | EPS next Q | - | Inst Own | 14.84% | Short Float | 0.27% | Perf Quarter | 2.53% |
| Income | 0.00B | P/S | 2.93 | EPS this Y | - | Inst Trans | -0.98% | Short Ratio | 0.53 | Perf Half Y | 49.1% |
| Sales | 0.03B | P/B | 2.87 | EPS next 5Y | - | ROA | 1.69% | Short Interest | 0.02M | Perf YTD | 61.22% |
| Book/sh | 3.45 | P/C | 10.16 | EPS past 3/5Y | 29.01% 4.06% | ROE | 2.57% | 52W High | -18.06% ($12.10) | Perf Year | 60.96% |
| Cash/sh | 0.98 | P/FCF | 21.39 | Sales past 3/5Y | 14.19% 12.5% | ROIC | 1.87% | 52W Low | 119.36% ($4.52) | Perf 3Y | 114.15% |
| Dividend Est. | - | EV/EBITDA | 22.03 | EPS Y/Y TTM | -54.03% | Gross Margin | 40.32% | Volatility(W/M) | 1.94% 3.75% | Perf 5Y | 7.18% |
| Dividend TTM | - | EV/Sales | 3.05 | Sales Y/Y TTM | 8.49% | Oper. Margin | 6.08% | ATR (14) | 0.34 | Perf 10Y | 36.06% |
| Dividend Ex-Date | - | Quick Ratio | 2.71 | EPS Q/Q | 258.99% | Profit Margin | 2.57% | RSI (14) | 42.36 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.75 | Sales Q/Q | 11.5% | SMA20 | -0.66% ($9.98) | Beta | 0.57 | Target Price | - |
| Payout | - | Debt/Eq | 0.4 | Earnings | 2026/8/13 | SMA50 | -6.27% ($10.57) | Rel Volume | 0.39 | Prev Close | $9.91 |
| Employees | 73 | LT Debt/Eq | 0.34 | EPS/Sales Surpr. | - | SMA200 | 22.55% ($8.09) | Avg Volume(3M) | 0.03M | Price | $9.91 |
| IPO | 1987/5/5 | Option/Short | No/Yes | Trades | 81 | Volume | 11,263 | Change | 0.05% |
Company
ICCC is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🐄 Elanco (ticker: ELAN) is an animal healthcare company that improves the health and productivity of dairy and beef cattle. The company develops, manufactures, and sells oral immunity products to prevent diarrhea (scours) in newborn calves, as well as diagnostic and therapeutic products for dairy cow mastitis, primarily operating in the US market.
Over the past 1 year, roughly in the middle
18% below its 1-year high.
ICCC makes money exceptionally well
6.08% of revenue is kept as operating profit.
Tap to view numbers
The price looks about right
Trading at 118.2 times earnings.
Tap to view numbers
Holding long would have paid off
Would have changed by +114.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 14.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
DFAC 0.00%
DFAT 0.00%
DFSU 0.00%
DXUV 0.00%It ranks #4 in the industry
Based on market cap of $90M.
ICCC $90M PER 118.2
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is ICCC?
ICCC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ICCC?
The market cap of ICCC is approximately $90M, ranking 4,618 within its sector.
What is the P/E ratio of ICCC?
ICCC has a P/E ratio of approximately 118.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ICCC?
ICCC has recorded a 52-week high of $12.10 and a low of $4.52.
